Research Radar — 2026-06-26
Methods & AI
Computational
Toward mechanistic virtual immune cells
Nature Biotechnology Published 2026-06-25 commentary DOI: 10.1038/s41587-026-03139-8
digital twin immune computational biology AI
Summary: This Comment outlines molecular and technical considerations for developing mechanistically grounded virtual immune cell models, bridging computational biology and immunology toward digital twin applications.
Why it matters: It articulates a vision for how mechanistic models of immune cells could complement AI-driven approaches, potentially transforming how we simulate and predict immune responses.
Why for Yiru: Directly relevant to digital twin and mechanistic AI interests — this is foundational reading for computational immunology direction.
Advances and challenges of splicing prediction with AI
Nature Genetics Published 2026-06-25 review DOI: 10.1038/s41588-026-02629-4
AI deep learning genomics splicing
Summary: This Review traces the evolution of computational approaches for splicing prediction from early statistical heuristics to modern artificial intelligence frameworks, highlighting progress and remaining challenges in precision medicine.
Why it matters: Splicing dysregulation underlies many genetic disorders; AI-based prediction tools are becoming critical for variant interpretation and therapeutic targeting.
Why for Yiru: AI for genomics — directly relevant to applying deep learning to biological sequence analysis problems.
Single-cell multiomics of neuron activation reveals context-specific genetics of brain disorders
Science Published 2026-06-25 research article DOI: 10.1126/science.adw3949
single-cell multi-omics genetics neuropsychiatric disorders
Summary: Most causal variants for neuropsychiatric disorders remain unknown. This study uses single-cell multiomics during neuronal activation to identify context-specific regulatory effects that are difficult to study in vivo at the population level.
Why it matters: Reveals how disease variants act in specific cellular contexts, providing a framework for understanding non-coding variant mechanisms in brain disorders.
Why for Yiru: Single-cell multiomics approach to complex disease genetics — directly relevant methodological interest.
Data-driven surrogates of rational design enable antimicrobial peptide optimization
Nature Machine Intelligence Published 2026-06-25 research article DOI: 10.1038/s42256-026-01258-0
AI deep learning generative AI drug discovery antimicrobial peptides
Summary: Rising pathogen drug resistance makes next-generation antimicrobial peptides a global priority. This work uses generative AI to rapidly propose new peptides with high therapeutic potential through data-driven rational design surrogates.
Why it matters: Antimicrobial resistance is a growing crisis; AI-driven peptide optimization offers a scalable path to novel therapeutics.
Why for Yiru: Generative AI applied to molecular design — directly relevant to AI-driven drug discovery interests.
DextraDemixer enables accurate identification of antigen-specific T cells from pMHC multimer experiments
bioRxiv (bioinformatics) Published 2026-06-24 research article DOI: 10.64898/2026.06.23.733339
T cell computational immunology single-cell TCR
Summary: DextraDemixer is a Bayesian hierarchical mixture model that disentangles antigen-specific T cells from background noise in pMHC multimer data, integrating negative controls and clonotype structure with calibrated uncertainty estimates.
Why it matters: Accurate identification of antigen-specific T cells is critical for understanding immune responses and developing immunotherapies; this tool addresses a key computational bottleneck.
Why for Yiru: Directly relevant to computational immunology and T cell analysis — Bayesian hierarchical modeling approach aligns with methodological interests.
Biomedical discoveries
Biomedicine
CD4+ T cells impair tumor growth through IL-3 and TNF-dependent vascular damage
Science Published 2026-06-18 research article DOI: 10.1126/science.ads7910
T cell immunotherapy tumor microenvironment macrophage cancer
Summary: This study identifies a tumor stroma-targeting mechanism where CD4+ T cells produce IL-3, which acts on myeloid cells to drive macrophage differentiation and TNF-dependent vascular damage in tumors.
Why it matters: Reveals a previously underappreciated role for CD4+ T cells in directly impairing tumor growth through vascular disruption, opening new avenues for immunotherapy combination strategies.
Why for Yiru: Core interest area — T cell biology, tumor microenvironment, and immunotherapy mechanisms.
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
Nature Medicine Published 2026-06-25 research article DOI: 10.1038/s41591-026-04481-9
immunotherapy biomarker cancer metabolomics machine learning
Summary: Mass-spectrometry-based metabolomic analysis of plasma from immunotherapy patients across 5 tumor types uses machine learning to identify metabolic signatures, revealing association of plasma histidine with prolonged survival.
Why it matters: Identifies clinically actionable metabolic biomarkers for immunotherapy response, potentially enabling patient stratification and dietary interventions.
Why for Yiru: Biomarker discovery and machine learning in cancer immunotherapy — directly relevant.
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
Nature Medicine Published 2026-06-25 research article DOI: 10.1038/s41591-026-04471-x
CAR-T immunotherapy multiple myeloma bispecific antibody
Summary: Phase 2 GMMG-HD10 trial evaluates BCMA×CD3 bispecific engager teclistamab with daratumumab/lenalidomide in transplant-eligible newly diagnosed multiple myeloma, showing encouraging response rates.
Why it matters: Advances the use of bispecific antibodies earlier in multiple myeloma treatment, potentially changing standard of care for newly diagnosed patients.
Why for Yiru: Immunotherapy clinical translation — bispecific antibodies and CAR-T in hematological malignancies.
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial
Nature Medicine Published 2026-06-25 research article DOI: 10.1038/s41591-026-04453-z
immunotherapy cancer breast cancer radiation
Summary: The Neo-CheckRay trial evaluates neoadjuvant immune-modulating stereotactic body radiation therapy with durvalumab ± oleclumab in early ER+HER2- breast cancer, demonstrating encouraging responses with durvalumab even in PD-L1-negative patients.
Why it matters: Suggests that combining radiation with immunotherapy may be effective in breast cancer subtypes not traditionally considered immunoresponsive.
Why for Yiru: Cancer immunotherapy clinical trial — relevant for understanding expanding indications for IO combinations.
Maternal trans-vaccenic acid shapes neonatal T cell development and early-life immune imprinting
Science Published 2026-06-18 research article DOI: 10.1126/science.aea4041
T cell immune development nutrition neonatal immunity
Summary: Maternal supplementation with trans-vaccenic acid (TVA) influences neonatal T cell development through breastfeeding, revealing how maternal nutrition impacts neonatal immune imprinting.
Why it matters: Reveals a mechanistic link between maternal diet and offspring immune system development, with implications for early-life immune programming and vaccination strategies.
Why for Yiru: T cell development and immune regulation — interesting cross-disciplinary connection between nutrition and immunology.
Three immunoregulatory signatures define non-productive HIV infection in stem cell memory CD4+ T cells
Nature Communications Published 2026-06-25 research article DOI: 10.1038/s41467-026-74551-6
T cell immune HIV transcriptomics
Summary: CD4+ TSCM cells harboring non-productive HIV proviruses display distinct immunoregulatory transcriptomic signatures, suggesting a tolerogenic environment driving immune evasion and HIV persistence.
Why it matters: Understanding how HIV persists in long-lived memory T cells is critical for developing curative strategies; these signatures may reveal new therapeutic targets.
Why for Yiru: T cell immunology and viral persistence — relevant to understanding immune evasion mechanisms.
Cross-disciplinary watchlist
Other Fields
Base editing reveals an essential role for NANOG in human embryogenesis
Nature Published 2026-06-25 research article DOI: 10.1038/s41586-026-10792-1
CRISPR base editing development embryogenesis
Summary: Base editing reveals an essential role for NANOG in human embryogenesis, demonstrating the power of precise genetic perturbation for studying early human development.
Why it matters: Provides direct functional evidence for NANOG's requirement in human embryogenesis, advancing our understanding of pluripotency and early development.
Why for Yiru: CRISPR and base editing tools applied to developmental biology — relevant for gene-editing methodology interests.
Lamprey 3D single-cell transcriptomics reveals ancestral and specialized features of the vertebrate brain
Science Published 2026-06-18 research article DOI: 10.1126/science.aea2535
single-cell transcriptomics evolution neuroscience
Summary: Using spatial transcriptomics and single-nucleus RNA-seq, this study generated a 3D molecular atlas of the lamprey brain identifying 209 distinct cell types and revealing ancestral and specialized features of the vertebrate brain.
Why it matters: Provides evolutionary context for vertebrate brain organization, revealing conserved cell types and specialized adaptations across 500 million years of evolution.
Why for Yiru: Single-cell and spatial transcriptomics at scale — relevant for methodological interests in building cellular atlases.
Ubiquitin-like proteins NEDD8 and SUMO2 control epithelial homeostasis, regeneration, and inflammation
Science Published 2026-06-25 research article DOI: 10.1126/science.aeb3900
multi-omics ubiquitin inflammation epithelial biology
Summary: Multiomic profiling implicated ubiquitin and related posttranslational networks in differentiation dynamics. Systematic perturbation of ubiquitin-like proteins revealed roles for NEDD8 and SUMO2 in epithelial homeostasis, regeneration, and inflammation.
Why it matters: Identifies specific ubiquitin-like proteins as critical regulators of epithelial barrier function and inflammatory responses, with potential therapeutic implications.
Why for Yiru: Multi-omics approach to biological regulation — relevant for methodology interests in systematic perturbation profiling.
Age and early life adversity shape heterogeneity of the epigenome across tissues in macaques
Science Published 2026-06-18 research article DOI: 10.1126/science.aea4922
epigenetics aging multi-tissue early life adversity
Summary: DNA methylation profiles across 14 tissues in 237 rhesus macaques reveal how age and early life adversity affect the epigenome across tissues, demonstrating tissue-specific epigenetic aging patterns.
Why it matters: Provides a comprehensive multi-tissue view of how both aging and early-life experiences shape the epigenome, with implications for understanding developmental programming of health.
Why for Yiru: Epigenetic regulation and aging — relevant for understanding tissue-specific epigenetic responses to environmental factors.
Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design
Science Published 2026-05-07 research article DOI: 10.1126/science.aec6396
vaccine HIV immunology antibody
Summary: Designed an epitope-focused simian-human immunodeficiency virus to induce broadly neutralizing HIV antibodies through a two-step mechanism, informing vaccine design strategies.
Why it matters: HIV vaccine development has been a decades-long challenge; this mechanistic insight into broadly neutralizing antibody induction could accelerate rational vaccine design.
Why for Yiru: Immunology and vaccine design — relevant for understanding B cell responses and epitope-focused immunogen strategies.
Friday delivery
BioTech News Delivery
At BIO 2026, industry wrestled with Washington politics, and making AI work better
STAT News Published 2026-06-25 news DOI: https://www.statnews.com/2026/06/25/bio-2026-industry-wrestled-washington-politics-ai/
biotech AI policy
Summary: Coverage from BIO 2026 highlights the biotech industry's challenges navigating Washington politics and the ongoing struggle to translate AI advances into tangible drug discovery outcomes.
Why it matters: Provides a snapshot of the macro environment shaping biotech investment and strategy, including policy uncertainty and AI adoption hurdles.
Why for Yiru: Biotech industry trends — relevant for understanding the broader context in which computational and translational research operates.
Gene-editing startup launches with $230 million and a Chinese licensing deal
STAT News Published 2026-06-23 news DOI: https://www.statnews.com/2026/06/23/gene-editing-startup-launches-230-million-chinese-licensing-deal/
gene editing biotech startup
Summary: A new gene-editing startup launches with $230 million in funding and a Chinese licensing deal, reflecting strong investor confidence in CRISPR-based therapeutic approaches.
Why it matters: Signals where venture capital is flowing in biotech and highlights the globalization of gene-editing therapeutic development.
Why for Yiru: Gene editing commercial landscape — relevant for tracking how CRISPR technologies are being translated to the clinic.
AbbVie to buy Apogee Therapeutics in nearly $11B deal
STAT News Published 2026-06-22 news DOI: https://www.statnews.com/2026/06/22/abbvie-apogee-acquisition-immunology-zumilokibart/
biotech M&A immunology
Summary: AbbVie agrees to acquire Apogee Therapeutics for nearly $11 billion, gaining immunology assets including zuimilokibart, reflecting the high value placed on inflammation and immunology pipelines.
Why it matters: One of the largest biotech M&A deals of the year, signaling strong demand for immunology therapeutics and validating Apogee's pipeline approach.
Why for Yiru: Biotech business landscape — relevant for understanding market dynamics in immunology therapeutics.
Eli Lilly dives into hair loss treatments with investment in AI startup Absci
STAT News Published 2026-06-24 news DOI: https://www.statnews.com/2026/06/24/eli-lilly-hair-loss-absci-ai/
AI drug discovery biotech
Summary: Eli Lilly invests in AI-driven drug discovery startup Absci to develop hair loss treatments, continuing the trend of major pharma partnerships with AI-native biotech companies.
Why it matters: Demonstrates how AI drug discovery platforms are being applied across therapeutic areas beyond oncology, expanding the addressable market for computational drug design.
Why for Yiru: AI in drug discovery — relevant for tracking how AI-native biotechs are partnering with big pharma.
Facing a brutal run, battered vaccine makers still see cause for hope
STAT News Published 2026-06-25 news DOI: https://www.statnews.com/2026/06/25/vaccine-makers-bio-2026-hope/
vaccines biotech
Summary: Despite a challenging period for vaccine companies, industry leaders at BIO 2026 express optimism about next-generation vaccine platforms and expanding applications beyond infectious diseases.
Why it matters: The vaccine industry is at a crossroads post-pandemic; understanding the strategic direction helps contextualize investment and innovation in this space.
Why for Yiru: Vaccine technology landscape — relevant for understanding where the field is heading beyond COVID-19.
FDA to launch pilot program to speed up early-stage clinical trials
STAT News Published 2026-06-22 news DOI: https://www.statnews.com/2026/06/22/fda-pilot-program-speed-early-stage-clinical-trials/
FDA clinical trials regulation
Summary: The FDA announces a new pilot program designed to streamline and speed up early-stage clinical trials, potentially lowering barriers for innovative therapies to reach first-in-human testing.
Why it matters: Regulatory innovation that could accelerate the pipeline from preclinical discovery to clinical testing, benefiting the entire biotech ecosystem.
Why for Yiru: Regulatory affairs — relevant for understanding how clinical development timelines may be evolving.